U.S. Markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
574.61-8.52 (-1.46%)
At close: 4:00PM EDT
Sign in to post a message.
  • c
    chris
    Sanofi reported dupixent sales, #$%$1.243. 20% increase from q1. Regn will get $733 million as their split. Almost $100 million more than q1 or $1/share. Roche Covid antibody sales of 429 chf vs 166 q1. If payout the same regn would get $173 million this quarter, up from $67 million or another $1/share. Analyst estimates are way too low. $12/share compared to last quarter without taking into account increase in Eylea sales and regn Covid antibody sales in the US. Lower dose approved, multiple conferences with executives mentioning they expect at least 1 million doses supplied to government, $2.1 billion in revenue. Profit will be huge from that. Maybe another $1.2 billion for $11/share. $23-25/share on 4.5-4.6 billion revenue. I?ll sit back and wait for as long as it takes for Wall Street to realize this stock deserves a much higher price. Patience all.
    Bullish
  • c
    chris
    FDA approved expanded indication for regn Covid antibody cocktail. Post exposure prophylaxis in high risk patients. Low volume days lately, it’ll all work itself out.
    Bullish
  • I
    InvestmentFreak
    Just bought more REGN. This is a great opportunity!
    Bullish
  • H
    Humble Warrior
    Another positive trial for dupixent in 5th indication. There is a whole pipeline in dupixent itself. Telling you again and again, hold this gem of a stock.
    Bullish
  • E
    Ed
    Amy Raskin from Chevy Chase Trust recommended REGN on Fast Money Halftime Report. Raskin said she added to her position in lower multiple stocks, including REGN. According to Raskin, REGN "is one of the best biotechs out there, trading at 16x, blows my mind that you can get in that cheaply right now." Later in the show she said that the "next decade wil be molecular medicine," and again recommended REGN
    as a value stock.
  • H
    Humble Warrior
    I am telling you again and again. This company is going to $1000 in the next 3-5 years. The science that is happening here is truly next level and it really helps that two CEOs are science nerds, not someone with an MBA degree. You can see just in last 3 years, their pipeline has exploded. If you go to their career section, they are hiring more and more scientist and if you have scientific acumen, from their website you can see that velocigene technology is realy accelerating the discovery of new targets.
    Bullish
  • P
    Paul
    REGN investing $1.8 billion in new research and production facilities. That strikes me as confidence that bigger things are ahead.
  • H
    Hal
    Hmmm ... We are holding steady on little or no news of immediate consequence. Today, with so much Blood on the Streets, it appears to now be an opportune time to change mounts for a better horse to ride on for those with reserve buying power.

    REGN is mostly held by institutions. Apparently, some institutional managers have been looking for an entry point while retail investors adjust their margined accounts. This portends well for our shares over the next few weeks. Hal
  • R
    Rex
    Nice move today, just wish the volume was up.
  • R
    Rex
    Once again, back to it's old tricks. Good news comes out, stock goes down - especially frustrating with the markets are up BIG.
  • R
    Rex
    Stuck in a trading range with limited buyers based on volume.
  • R
    Ron
    Did anybody analyse the 1H numbers from Roche and distillate the revenue for the monoclonal anti-bodies for both Regeneron and Roche ? I did.. ;-) EU / INTL.
  • t
    takeiteasyu2
    This has been a great stock since March around 455. I bought $100,000 worth & have $30,000 profit now. REGN is PE 11 and has $50/share earnings. Great stock!
  • R
    Richard
    2Q earnings Aug 5. Potential buyers may be waiting too see that, so, absent good news before then, we could drift or even drop. That would allow overbought momentum to correct and set up a post-earnings rally. Risk appears the be to 575.
  • I
    InvestmentFreak
    600 next!
    Bullish
  • M
    Mitja
    Well, CEO with his 138 millions fat paycheck for 2020 is laughing at this. Do you enjoy this price action Rex and Richard?
  • R
    Rex
    drifting, drifting, drifting...
  • C
    Costy
    Japan becomes first country to approve use of Regenerons antibody cocktail. This is great news.
  • H
    Humble Warrior
    Collaboration with AZ!! That's a testament to exceptional work being done at Regeneron. Obesity is a huge hugee market!
    Bullish
  • I
    InvestmentFreak
    600+ here we come!
    Bullish